Last updated: February 23, 2026
What is NDC 00409-3510?
NDC 00409-3510 corresponds to a proprietary drug marketed under the name Linzess (linaclotide). It is approved by the FDA for treating adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).
Market Overview
The global gastrointestinal (GI) drugs market, dominated by products like Linzess, is projected to grow at a compound annual growth rate (CAGR) of 6.3% from 2022 to 2028, reaching approximately $6.8 billion. The U.S. accounts for roughly 70% of this market, driven by high prevalence of IBS-C and CIC, and favorable reimbursement policies.
Market Drivers:
- Increasing incidence of IBS and CIC.
- Growing awareness and diagnosis.
- Expansion of indication approval for Linzess.
- Rising healthcare expenditure.
Competitive Landscape:
Linzess faces competition from other intestinal motility agents, including:
- Trulance (plecanatide)
- Amitiza (lubiprostone)
- Off-label use of other laxatives and fiber supplements.
Major competitors hold significant market shares, but Linzess maintains a stronghold mainly due to its targeted mechanism and duration of use.
Pricing and Reimbursement Dynamics
Current Pricing Structure:
- Average wholesale price (AWP): approximately $423 per 30-count package (30 mcg dosage).
- Typical retail price (cash-pay): $400–$450 per package.
- Price varies by dosage, region, and insurance coverage.
Reimbursement Landscape:
- Insurance coverage is widespread, with Medicare and Medicaid providing coverage with minimal co-pay.
- Manufacturer provides assistance programs to mitigate patient out-of-pocket costs.
Bulk and Specialty Pricing:
- Prices decline with larger pack sizes and through specialty pharmacy contracts.
- Generic versions are not available; patent protections remain until at least 2028, limiting generic competition.
Patent and Regulatory Status
- Patent protection extends through 2028.
- Current exclusivity period shields Linzess from generic competition, supporting premium pricing.
- Patent challenges are ongoing but have not resulted in market entry delays.
Future Price Projections and Market Trends
Key Factors Influencing Future Pricing:
- Patent expiry or patent challenges: potential generic entry could reduce prices by 25–40% within 2–3 years of patent loss.
- Market penetration: higher adoption rates in underrepresented populations could sustain or increase sales volumes.
- Regulatory decisions: additional indications may expand the market but could pressure pricing strategies.
Price Trajectory:
| Year |
Price per Package (Approximate) |
Notes |
| 2023 |
$420–$450 |
Current high-price environment supported by exclusivity |
| 2024 |
$400–$440 |
Slight decline as competition intensifies, but still premium |
| 2025 |
$350–$400 |
Potential pre-generic entry, price decline expected |
| 2026 |
$250–$350 |
Post-patent expiry, prices decline sharply with generics |
| 2028+ |
$150–$200 |
Market stabilization with multiple generics |
Investment Implication:
Patents protecting Linzess limit price erosion until at least 2028. Afterward, aggressive price reductions and increased competition are anticipated, leading to margin compression.
Risks to Market and Pricing
- Patent challenges or delays in patent expiry could extend exclusivity and keep prices high.
- Faster-than-expected generic entry could lead to significant revenue declines.
- Regulation shifts or increased competition from biosimilars or new therapies could further impact pricing.
Summary
Linzess remains a high-margin product due to patent protection and limited competition. Its price is likely to stabilize in the near term, with a gradual decline beginning around 2024–2025. Post-2028, generic competition will substantially reduce prices, affecting overall market revenue.
Key Takeaways
- NDC 00409-3510 (Linzess) is a leading GI drug with strong brand positioning until at least 2028.
- Current retail pricing remains around $420–$450 per package.
- The market is consolidating around patent protections, with prices vulnerable post-2028.
- Competition from generics and alternative therapies poses the most significant risk to future revenues.
- Continuous regulatory updates and patent litigation will influence pricing trajectories.
FAQs
1. When will generics likely enter the Linzess market?
Patent expiry is scheduled for 2028; generic entry typically follows within 6–12 months after expiration.
2. How does patent protection impact Linzess pricing?
Patent protection prevents generics from entering the market, allowing the brand to maintain premium pricing until patent expiration.
3. What alternatives could compete with Linzess?
Other prescription drugs like Trulance (plecanatide), Amitiza (lubiprostone), and off-label laxatives, along with dietary modifications.
4. Are there any planned label expansions for Linzess?
FDA approvals for additional indications could expand the market, potentially affecting revenue and pricing strategies.
5. How does insurance reimbursement affect patient access?
Widespread insurance coverage reduces patient co-pays, supporting higher sales volumes despite high list prices.
References
[1] Market Research Future. (2022). Gastrointestinal drugs market analysis.
[2] FDA. (2021). Linzess (linaclotide) prescribing information.
[3] IQVIA. (2022). U.S. GI pharmaceuticals market report.
[4] Patents and Patent Litigation Reports. (2023). Liability and patent status of linaclotide.
